Phase I/II study of oral administration of S 49076 given in combination with gefitinib in patients with EGFR mutated advanced non-small-cell lung cancer who have progressed after treatment with EGFR tyrosine kinase inhibitor.
Phase of Trial: Phase I/II
Latest Information Update: 26 Oct 2017
At a glance
- Drugs S-49076 (Primary) ; Gefitinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors IRIS
- 18 Oct 2017 Preliminary data (n=17) presented at the 18th World Conference on Lung Cancer.
- 08 Sep 2017 According to trial design presented at 42nd European Society for Medical Oncology Congress, the end of phase I is expected in Q3 2017.
- 08 Sep 2017 Trial design presented at 42nd European Society for Medical Oncology Congress.